Deal Watch: Merck’s Next Move In Cancer Immunotherapy Is BET Inhibitor, Bispecifics Gaining Steam

Pfizer pays Opko $295 million up front for global rights to develop and commercialize a long-acting recombinant human growth hormone, Roche and Novo Nordisk buy into bispecific technology and Janssen signs on with Halozyme, as Pfizer did two years earlier, to use the ENHANZE delivery platform technology with its own candidates against five targets.